4th Palermo Conference on INNOVATIVE THERAPIES FOR LYMPHOID MALIGNANCIES
Published online 31 July 2009
Haematologica, Vol 94, Issue 12, 1732-1742 doi:10.3324/haematol.2009.007583
Copyright © 2009 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Peinemann et al. Supplementary Appendix
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Peinemann, F.
Right arrow Articles by Lange, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peinemann, F.
Right arrow Articles by Lange, S.

Aplastic anemia

Unrelated donor stem cell transplantation in acquired severe aplastic anemia: a systematic review

Frank Peinemann1, Ulrich Grouven1,3, Nicolaus Kröger2, Max Pittler1, Beate Zschorlich1, Stefan Lange1

1 IQWiG Institute for Quality and Efficiency in Health Care, Cologne
2 Interdisciplinary Clinic for Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg
3 Hannover Medical School, Hannover, Germany

Correspondence: Frank Peinemann, IQWiG Institute for Quality and Efficiency in Health Care, Dillenburger Str. 27, 51105 Cologne, Germany. E-mail: frank.peinemann{at}iqwig.de

Acquired severe aplastic anemia is a rare disease characterized by an immune-mediated functional impairment of hematopoietic stem cells. Transplantation of these cells from unrelated donors is a treatment option frequently offered to patients after failed immunosuppressive therapy. The aim was to investigate the outcome of these patients treated with unrelated donor transplants. Systematic literature searches were performed in MEDLINE, EMBASE, and The Cochrane Library. All databases were searched from inception to June 2009. Only full-text publications and studies including at least 10 patients were considered. The primary outcome was 5-year overall survival from the day of transplantation and the secondary outcomes were graft failure and graft-versus-host disease. A meta-analysis of survival estimates was conducted and heterogeneity was investigated. A total of 18 studies, one controlled trial and 17 case series were identified. The overall survival at five years and the corresponding confidence interval was stated in 8 studies and ranged from 28% to 94%. A meta-analysis revealed considerable heterogeneity between the studies that could not be explained and was also present in subgroups of the studies. The proportion of acute graft failure was 45% in one study using only umbilical cord blood, and it was reported to be 0–26% in 15 studies using mainly bone marrow as stem cell source after different follow-up periods. Acute GVHD grade II–IV was reported for 8–86% and extensive chronic GVHD for 0–38% of the evaluated patients in 16 studies. Recipient age, human leukocyte antigen match, performance status, year of transplantation, and conditioning with serotherapy were identified as significant factors for improved survival. Unrelated donor hematopoietic stem cell transplantation in patients with acquired severe aplastic anemia after failure to immunosuppressive therapy is a treatment option. A stable physical condition of the patients before receiving the transplant (for example, performance and age) may be associated with a better survival. Detailed HLA-matching facilitated by DNA-based typing, among other factors, may have contributed to recent improvements on survival after unrelated donor HSCT as a second-line treatment.

Key words: donor stem cell transplantation, aplastic anemia, systematic review.